About: Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Creator	Stein, Cy Agarwal, Neeraj Babiker, Hani Barata, Pedro Bryce, Alan Garje, Rohan Gerendash, Benjamin Hatton, Whitley Jaeger, Ellen Kiedrowski, Lesli Layton, Jodi Ledet, Elisa Lewis, Brian Nussenzveig, Roberto Sartor, Oliver Saylor, Philip
source	Medline; PMC
abstract	To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated with immune checkpoint inhibitors. Retrospective analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and MSI-H tumor detected by a commercially available cfDNA NGS assay Guardant360 (G360, Guardant Health) at eight different Academic Institutions in the USA, from September 2018 to April 2020. From a total of 14 MSI-H metastatic prostate cancer patients at participating centers, nine patients with mCRPC with 56% bone, 33% nodal, 11% liver and 11% soft-tissue metastases and a median PSA of 29.3 ng/dL, were treated with pembrolizumab after 2 lines of therapy for CRPC. The estimated median time on pembrolizumab was 9.9 (95% CI 1.0 to 18.8) months. Four patients (44%) achieved PSA50 after a median of 4 (3–12) weeks after treatment initiation including three patients with >99% PSA decline. Among the patients evaluable for radiographic response (n=5), the response rate was 60% with one complete response and two partial responses. Best response was observed after a median of 3.3 (1.4–7.6) months. At time of cut-off, four patients were still on pembrolizumab while four patients discontinued therapy due to progressive disease and one due to COVID-19 infection. Half of the patients with PSA50 had both MSI-H and pathogenic alterations in BRCA1 and BRCA2 in their G360 assays. The use of liquid biopsy to identify metastatic prostate cancer patients with MSI-H is feasible in clinical practice and may overcome some of the obstacles associated with prostate cancer tumor tissue testing. The robust activity of pembrolizumab in selected patients supports the generalized testing for MSI-H.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1136/jitc-2020-001065
bibo:pmid	32788235
has license	cc-by-nc
sha1sum (hex)	ec98fea42f854dd9bb1f7fd84edaf837acc387c9
schema:url	https://doi.org/10.1136/jitc-2020-001065
resource representing a document's title	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
has PubMed Central identifier	PMC7422632
has PubMed identifier	32788235
schema:publication	J Immunother Cancer
resource representing a document's body	covid:ec98fea42f854dd9bb1f7fd84edaf837acc387c9#body_text
is schema:about of	named entity 'metastatic prostate cancer' named entity 'pembrolizumab' named entity 'MSI-H' named entity 'radiographic' named entity 'repeating units' named entity 'indels' named entity 'ATM' named entity 'metastatic' named entity 'pembrolizumab' named entity 'PD-1 inhibitors' named entity '0.9' named entity 'MSI-H' named entity 'advanced prostate cancer' named entity 'PCR-based' named entity 'poly ADP ribose polymerase' named entity '3.5' named entity 'prostate cancer' named entity 'PD-1 inhibitors' named entity 'NGS' named entity 'MSI-H' named entity 'radiographs' named entity 'solid tumors' named entity 'lymph nodes' named entity 'ATM' named entity 'Castration-resistant prostate cancer' named entity 'MSI-H' named entity 'BRCA1' named entity 'atezolizumab' named entity 'predictive biomarker' named entity 'SNVs' named entity 'MSI-H' named entity 'CRPC' named entity 'ipilimumab' named entity 'Group 3' named entity 'MSI-H' named entity 'CRPC' named entity 'national guidelines' named entity 'MSI-H' named entity 'MSI-H' named entity 'case series' named entity 'receptor' named entity 'NGS' named entity 'pembrolizumab' named entity 'castrate' named entity 'prostate cancer' named entity 'PSA' named entity 'MSI-H' named entity 'metastatic' named entity 'PSA' named entity 'pembrolizumab' named entity 'PD-L1' named entity 'pembrolizumab' named entity '14.5' named entity 'MLH1' named entity 'cell therapies' named entity 'MSI-H' named entity 'CRPC' named entity 'immune checkpoint inhibitors' named entity 'metastases' named entity 'PSA' named entity 'radiographic' named entity 'cell-free DNA' named entity 'Guardant Health' named entity 'tumor' named entity 'MSI-H' named entity 'microsatellite instability'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software